MedTrace Logo

Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC

NCT03494803 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-12-22

No results posted yet for this study

Summary

Prostate cancer is a leading cause of mortality and morbidity.

The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC, T-cells and circulated tumor DNA in prostate cancer patients.

Conditions

Sponsors & Collaborators

  • Kazakh Research Institute of Oncology & Radiology

    collaborator OTHER

  • HKGepitherapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03494803 on ClinicalTrials.gov